2. UroToday Home
  3. Video Lectures

Overactive Bladder Videos

Overactive Bladder Syndrome and Poor Bladder Compliance: Definitions and Distinction - Mitchell Goldenberg
Comparison of Mirabegron, Vibegron, and Anticholinergics for Incident Dementia in Overactive Bladder Treatment - Adonis Hijaz & David Sheyn
Implementing Minimally Invasive Overactive Bladder Procedures in the Clinic - Ariana Smith
Analysis on the Current State and Future of Overactive Bladder Pharmacotherapy - Christopher Chapple
Machine Learning Studied to Predict Response to Advanced Overactive Bladder Therapies - Sandip Vasavada
Technical Considerations for Tibial Nerve Stimulation Implants - John Heesakkers
Tibial Nerve Stimulation Devices for Lower Urinary Tract Disorders - John Heesakkers
Overview of Neuromodulation Techniques for Lower Urinary Tract Disorders - John Heesakkers
Frailty, Socioeconomics, and Specialist Access Drive Overactive Bladder Care Disparities - Ekene Enemchukwu
COURAGE Trial: Vibegron for BPH Patients with Persistent OAB Symptoms - David Staskin
Optimizing Overactive Bladder Treatment: Phenazopyridine's Cost-Effective Approach - Anjali Kapur
Oxybutynin-Associated Cognitive Impairment: Evidence and Implications for Overactive Bladder Treatment - Beyond the Abstract
Emerging Technologies in Urology: A Glimpse Into Tibial Nerve Stimulation for Bladder Dysfunction Treatment - Diane Newman & Howard Goldman
Revolutionizing Urodynamics: Uromonitor's Comfortable, Real-Life Bladder Pressure Tracking - Diane Newman & Howard Goldman
Phase 2a Trial Results: Promising Gene Therapy for Overactive Bladder - URO-902 Safety and Efficacy Evaluation - Kenneth Peters
Interpretation of the Meaningfulness of Symptom Reduction with Vibegron in Patients with Overactive Bladder: Analyses from EMPOWUR - Beyond the Abstract
Mechanistic Pathway Through Which Saphenous Nerve Stimulation Can Modulate Bladder Function - Paul Yoo
Developing A Novel Neuromodulation Therapy for Treating Overactive Bladder - Anne Agur
The Effects of Vibegron on Ambulatory Blood Pressure in Patients With Overactive Bladder - Michael A. Weber
The OAB Clinical Care Pathway Mobile APP - Stephen Kraus
GEMTESA® (vibegron) for the Treatment of Patients with Overactive Bladder FDA Approved - Scott A. MacDiarmid
Advancements in Pharmacological and Device-Based OAB Treatment Options - Eric Rovner
Incontinence Options for Men and Women: Is It Safe? - Eric S. Rovner
A Contemporary Assessment of Nocturia - Mikel Gray